In the last few years, the clinical landscape of CF has changed enormously, with 73% of UK CF patients on CFTR modulator therapy in 2023 (64% on elexacaftor/tezacaftor/ivacaftor (ETI)) [6]. This evidence concerns the gene CFTR and cystic fibrosis.